Angola vs Namibia: Statin use vs. average non-HDL cholesterol levels
Angola
2.8
in 2018
Namibia
2.8
in 2018
Angola rank
163rd
Namibia rank
163rd
Statin use vs. average non-HDL cholesterol levels over time
- Angola
- Namibia
How they compare
Angola currently reports 2.8 against 2.8 in Namibia, a difference of 0.
The two have swapped places 4 times across 39 shared years of data; in 1980 it was Namibia ahead.
Angola ranks 163rd and Namibia ranks 163rd of 191 countries.
Across the 4 decades both report, Angola averaged higher in 3 and Namibia in 1.
Head to head by decade
| Decade | Angola | Namibia | Difference | Ahead |
|---|---|---|---|---|
| 1980s | 2.57 | 2.61 | 0.04 | Namibia |
| 1990s | 2.75 | 2.7 | 0.05 | Angola |
| 2000s | 2.83 | 2.76 | 0.07 | Angola |
| 2010s | 2.84 | 2.8 | 0.0444 | Angola |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher statin use vs. average non-hdl cholesterol levels, Angola or Namibia?
- Angola, at 2.8 against 2.8 in Namibia as of 2018.
- What is the difference in statin use vs. average non-hdl cholesterol levels between Angola and Namibia?
- 0, with Angola ahead.
- How many years of comparable data are there for Angola and Namibia?
- 39 years are reported by both, from 1980 to 2018.
- How do Angola and Namibia rank globally for statin use vs. average non-hdl cholesterol levels?
- Angola ranks 163rd and Namibia ranks 163rd of 191 countries.
- Where does this data come from?
- World Health Organization – Global Health Observatory (2026) – with minor processing by Our World in Data, published as Statin use vs. average non-HDL cholesterol levels. Statizoid refreshes it automatically from the source and publishes the full history for both places.
Individual pages
About this data
The use of statins in the population. This is compared to average non-HDL cholesterol levels, in mmol/L. Statins are a type of drug that reduce non-HDL cholesterol levels, and are used to treat and prevent cardiovascular diseases in people at heightened risk. Their usage is measured in Defined Daily Doses, per 1,000 people.